Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

467 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapies.
Chan A, Cameron MC, Garden B, Boers-Doets CB, Schindler K, Epstein JB, Choi J, Beamer L, Roeland E, Russi EG, Bensadoun RJ, Teo YL, Chan RJ, Shih V, Bryce J, Raber-Durlacher J, Gerber PA, Freytes CO, Rapoport B, LeBoeuf N, Sibaud V, Lacouture ME. Chan A, et al. Among authors: schindler k. Support Care Cancer. 2015 Aug;23(8):2231-44. doi: 10.1007/s00520-014-2564-x. Epub 2015 Jan 7. Support Care Cancer. 2015. PMID: 25564221 Free PMC article. Review.
Incidence and risk of xerosis with targeted anticancer therapies.
Valentine J, Belum VR, Duran J, Ciccolini K, Schindler K, Wu S, Lacouture ME. Valentine J, et al. Among authors: schindler k. J Am Acad Dermatol. 2015 Apr;72(4):656-67. doi: 10.1016/j.jaad.2014.12.010. Epub 2015 Jan 27. J Am Acad Dermatol. 2015. PMID: 25637330 Review.
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.
Naidoo J, Page DB, Li BT, Connell LC, Schindler K, Lacouture ME, Postow MA, Wolchok JD. Naidoo J, et al. Among authors: schindler k. Ann Oncol. 2015 Dec;26(12):2375-91. doi: 10.1093/annonc/mdv383. Epub 2015 Sep 14. Ann Oncol. 2015. PMID: 26371282 Free PMC article. Review.
Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1.
Naidoo J, Schindler K, Querfeld C, Busam K, Cunningham J, Page DB, Postow MA, Weinstein A, Lucas AS, Ciccolini KT, Quigley EA, Lesokhin AM, Paik PK, Chaft JE, Segal NH, D'Angelo SP, Dickson MA, Wolchok JD, Lacouture ME. Naidoo J, et al. Among authors: schindler k. Cancer Immunol Res. 2016 May;4(5):383-9. doi: 10.1158/2326-6066.CIR-15-0123. Epub 2016 Feb 29. Cancer Immunol Res. 2016. PMID: 26928461 Free PMC article.
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.
Naidoo J, Page DB, Li BT, Connell LC, Schindler K, Lacouture ME, Postow MA, Wolchok JD. Naidoo J, et al. Among authors: schindler k. Ann Oncol. 2016 Jul;27(7):1362. doi: 10.1093/annonc/mdw141. Epub 2016 Apr 12. Ann Oncol. 2016. PMID: 27072927 Free PMC article. No abstract available.
What does the future hold for immunotherapy in cancer?
Naidoo J, Li BT, Schindler K, Page DB. Naidoo J, et al. Among authors: schindler k. Ann Transl Med. 2016 May;4(9):177. doi: 10.21037/atm.2016.04.05. Ann Transl Med. 2016. PMID: 27275490 Free PMC article. No abstract available.
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators. Salloway S, et al. N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839. N Engl J Med. 2014. PMID: 24450891 Free PMC article. Clinical Trial.
467 results